Formulary e-News:

Having trouble viewing this email? View in a browser.

You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.

Subscribe Now

to Formulary e-News
Formulary, A peer-reviewed drug management journal for managed care and hospital decision-makers
Part of the Modern Medicine Network

e-News

FormularyJournal.com

April 1, 2011
Formulary
Home Medication Safety FDA Actions Latest News Policy Watch Drug Watch
More from
Formulary
Nonadherence to therapy common in SLE
5α-reductase inhibitors in BPH linked with adverse sexual effects
Vimovo well tolerated by arthritis patients at risk for gastric ulcers
High-dose clopidogrel does not reduce mortality after PCI

Survey
This month we would like to know...

Do you support The Preserving Access to Life-Saving Medicines Act, which would increase FDA's authority to prevent prescription drug shortages?

• Yes


• No

Click Here to Vote

Digital Edition
Formulary Digital Edition View Current Edition Subscribe to the Digital Edition

FDA lopinavir/ritonavir label change warns of serious health risks
in premature babies

FDA notified healthcare professionals of serious health risks that have been reported in premature babies receiving lopinavir/ritonavir (Kaletra, Abbott) oral solution. Read full article.
divider

Prolonged use of proton pump inhibitors linked with hypomagnesemia

Prescription proton pump inhibitors may cause hypomagnesemia if taken for prolonged periods of time (in most cases longer than 1 year), according to FDA. Read full article.
divider

FDA approves first new drug for lupus in 56 years

FDA approved belimumab (Benlysta, Human Genome Sciences and GlaxoSmithKline) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus who are receiving standard therapy. Read full article.

divider

FDA approves new treatment for a type of late-stage skin cancer

FDA has approved ipilimumab (Yervoy, Bristol-Myers Squibb) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer. Read full article.

divider

Metformin has highest benefit-risk profile in type 2 diabetes

Evidence supports metformin as a first-line agent to treat type 2 diabetes, according to a study in the March 14, 2011, online edition of the Annals of Internal Medicine. Read full article.

divider

FDA expands approval of shingles vaccine

FDA has approved an expanded age indication for Zoster Vaccine Live, (Zostavax, Merck) for the prevention of herpes zoster, commonly known as shingles, in adults aged 50 years and older. Read full article.

divider

FDA issues labeling change for OTC proton pump inhibitors

The risk of fracture is unlikely in patients taking short-term, low-dose proton pump inhibitors, according to a review of available safety data by FDA. Read full article.

divider

Top 5 Web Stories

  1. Dabigatran: A new orally available anticoagulant for prevention of strokes and thrombosis in patients with atrial fibrillation

  2. Contraceptive treatments: A review of current hormone options and newer agents for women

  3. Study finds different opioids offer variable safety in older adults with noncancer pain

  4. Dabigatran may be a cost-effective alternative to warfarin for stroke prevention in atrial fibrillation

  5. Risedronate sodium delayed-release tablets (Atelvia): A once-weekly oral bisphosphonate
divider

Contact Us

Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Healthcare

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.